3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
9
Prostatic Neoplasms
9
Breast Neoplasms
8
Pancreatic Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
5
Stomach Neoplasms
5
Ovarian Neoplasms
5
Colorectal Neoplasms
5
Urologic Neoplasms
4
Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Hepatocellular
4
Urethral Neoplasms
3
Thyroid Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Sarcoma
3
Salivary Gland Neoplasms
3
Rectal Neoplasms
3
Lung Neoplasms
3
Gallbladder Neoplasms
3
Colonic Neoplasms
3
Breast Neoplasms, Male
3
Vulvar Neoplasms
2
Vipoma
2
Vaginal Neoplasms
2
Uterine Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Interventions
Nivolumab
5
pembrolizumab
4
Ipilimumab
2
Drug Therapy
2
Biopsy
2
poly ICLC
1
pertuzumab
1
osimertinib
1
montanide ISA 51
1
liposomal doxorubicin
1
flt3 ligand protein
1
cobimetinib
1
cemiplimab
1
cc-486
1
brodalumab
1
Trastuzumab
1
Tissue Banks
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
Trastuzumab
×
Genitourinary
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled